Skip to main content
Midas Edge

ANI PHARMACEUTICALS INC

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

ANIP$67.79+0.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 6. Exhibits

The exhibits listed in the Index to Exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.

INDEX TO EXHIBITS

Exhibit No.Description
10.1Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Stephen P. Carey.
10.2Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Meredith Cook.
10.3Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Krista Davis.
10.4Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Chad Gassert.
10.5Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Ori Gutwerg.
10.6Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Nikhil Lalwani.
10.7Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Christopher Mutz.
10.8Amendment No. 1 to Executive Employment Agreement, dated October 27, 2025, by and between ANI Pharmaceuticals, Inc. and Muthusamy Shanmugam.
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a).
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a).
32.1*Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase
101.DEFInline XBRL Taxonomy Extension Definition Linkbase
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
  • In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.